‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. — Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here. CAR T-cell therapy is not yet ready for clinical practice, but enrolling patients in the growing number of clinical trials can help […]
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma
NASHVILLE, Tenn. — Building on the existing immune checkpoint inhibitor (ICI) platform, new treatment strategies for renal cell carcinoma (RCC) seek to adapt the cancer’s immunity cycle to inform development of more effective therapies, according to a review presented here. Limited options exist beyond anti-VEGF and ICI-based strategies for patients with advanced disease, particularly those […]
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma
NASHVILLE, Tenn. — An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small clinical trial showed. Overall, 12 of 32 patients responded to zanzalintinib, including four of 17 evaluable patients with prior exposure to cabozantinib and eight of 14 without. All but one […]
Patients With Narcolepsy Face Mood and Pain Disorders
NASHVILLE, Tenn. — People with narcolepsy frequently had mood and pain comorbidities that complicated diagnosis and treatment plans, observational data showed. In a propensity-matched cohort analysis of more than 4,000 individuals, people with narcolepsy were more than twice as likely to be diagnosed with depression (OR 2.11, 95% CI 1.86-2.40, P<0.001) or chronic pain syndrome […]